HomeCompareCTVIF vs JNJ

CTVIF vs JNJ: Dividend Comparison 2026

CTVIF yields 23.97% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTVIF wins by $240868805.12M in total portfolio value
10 years
CTVIF
CTVIF
● Live price
23.97%
Share price
$0.18
Annual div
$0.04
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$240868805.15M
Annual income
$238,953,877,082,691.20
Full CTVIF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CTVIF vs JNJ

📍 CTVIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTVIFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTVIF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTVIF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTVIF
Annual income on $10K today (after 15% tax)
$2,037.60/yr
After 10yr DRIP, annual income (after tax)
$203,110,795,520,287.50/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CTVIF beats the other by $203,110,795,516,301.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTVIF + JNJ for your $10,000?

CTVIF: 50%JNJ: 50%
100% JNJ50/50100% CTVIF
Portfolio after 10yr
$120434402.59M
Annual income
$119,476,938,543,690.30/yr
Blended yield
99.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CTVIF
No analyst data
Altman Z
1.4
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTVIF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTVIFJNJ
Forward yield23.97%2.13%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$240868805.15M$30.3K
Annual income after 10y$238,953,877,082,691.20$4,689.40
Total dividends collected$240741755.37M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CTVIF vs JNJ ($10,000, DRIP)

YearCTVIF PortfolioCTVIF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$15,494$4,794.35$10,592$272.30+$4.9KCTVIF
2$30,464$13,885.10$11,289$357.73+$19.2KCTVIF
3$83,625$51,028.11$12,123$472.89+$71.5KCTVIF
4$351,298$261,819.72$13,141$629.86+$338.2KCTVIF
5$2,431,733$2,055,843.68$14,408$846.81+$2.42MCTVIF
6$29,201,630$26,599,675.96$16,021$1,151.60+$29.19MCTVIF
7$628,300,048$597,054,304.01$18,122$1,588.22+$628.28MCTVIF
8$24,683,823,123$24,011,542,071.65$20,930$2,228.20+$24683.80MCTVIF
9$1,789,652,395,610$1,763,240,704,868.75$24,792$3,191.91+$1789652.37MCTVIF
10$240,868,805,145,994$238,953,877,082,691.20$30,274$4,689.40+$240868805.12MCTVIF

CTVIF vs JNJ: Complete Analysis 2026

CTVIFStock

China Travel International Investment Hong Kong Limited, an investment holding company, provides travel and tourism services. Its Tourist Attraction and Related Operations segment operates theme parks, scenic spots, cable car systems, skiing facilities, hot spring resorts, and other resorts, as well as engages in arts performance and tourism property development activities in Mainland China. The company's Travel Agency, Travel Document, and Related Operations segment provides travel agency, travel document, and related services in Hong Kong, Mainland China, South East Asia, Oceania, the United States, and countries in the European Union. Its Hotel Operations segment offers hotel accommodation, and food and beverage services in Hong Kong, Macau, and Mainland China. The company's Passenger Transportation Operations segment provides cross-border transportation services to individuals travelling between Hong Kong, Macau, and Mainland China; and vehicle and vessel rental and charter operations in Hong Kong, Macau, and Mainland China. It also operates golf clubs; trades in computer equipment and provides computer services; and offers travel and air ticketing agency, entry permit handling agency, fuel supply, ship repairing, and logistics and courier services. In addition, the company is involved in property investment; software system development; and shipping and shipping management activities, as well as conference and exhibition operations. The company was incorporated in 1992 and is based in Central, Hong Kong. China Travel International Investment Hong Kong Limited is a subsidiary of China Travel Service (Holdings) Hong Kong Limited.

Full CTVIF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CTVIF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTVIF vs SCHDCTVIF vs JEPICTVIF vs OCTVIF vs KOCTVIF vs MAINCTVIF vs ABBVCTVIF vs MRKCTVIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.